首页> 外文期刊>Current medical research and opinion >The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality
【24h】

The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality

机译:ICSD-3和DSM-5诊断发作性睡病的指南:临床意义和实用性

获取原文
获取原文并翻译 | 示例
       

摘要

Narcolepsy is a chronic neurological disease manifesting as difficulty with maintaining continuous wake and sleep. Clinical presentation varies but requires excessive daytime sleepiness (EDS) occurring alone or together with features of rapid-eye movement (REM) sleep dissociation (e.g., cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis), and disrupted nighttime sleep. Narcolepsy with cataplexy is associated with reductions of cerebrospinal fluid (CSF) hypocretin due to destruction of hypocretin peptide-producing neurons in the hypothalamus in individuals with a specific genetic predisposition. Updated diagnostic criteria include the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) and International Classification of Sleep Disorders Third Edition (ICSD-3). DSM-5 criteria require EDS in association with any one of the following: (1) cataplexy; (2) CSF hypocretin deficiency; (3) REM sleep latency 15minutes on nocturnal polysomnography (PSG); or (4) mean sleep latency 8minutes on multiple sleep latency testing (MSLT) with 2 sleep-onset REM-sleep periods (SOREMPs). ICSD-3 relies more upon objective data in addition to EDS, somewhat complicating the diagnostic criteria: 1) cataplexy and either positive MSLT/PSG findings or CSF hypocretin deficiency; (2) MSLT criteria similar to DSM-5 except that a SOREMP on PSG may count as one of the SOREMPs required on MSLT; and (3) distinct division of narcolepsy into type 1, which requires the presence of cataplexy or documented CSF hypocretin deficiency, and type 2, where cataplexy is absent, and CSF hypocretin levels are either normal or undocumented. We discuss limitations of these criteria such as variability in clinical presentation of cataplexy, particularly when cataplexy may be ambiguous, as well as by age; multiple and/or invasive CSF diagnostic test requirements; and lack of normative diagnostic test data (e.g., MSLT) in certain populations. While ICSD-3 criteria reflect narcolepsy pathophysiology, DSM-5 criteria have greater clinical practicality, suggesting that valid and reliable biomarkers to help standardize narcolepsy diagnosis would be welcomed.
机译:发作性睡病是一种慢性神经系统疾病,表现为难以维持持续的唤醒和睡眠。临床表现各不相同,但需要单独或与快速眼动(REM)睡眠解离(例如,瘫痪,催眠/催眠幻觉,睡眠麻痹)和夜间睡眠中断一起出现的过度白天嗜睡(EDS)。患有发作性猝死的发作性睡病与具有特定遗传易感性的个体下丘脑中产生降血钙素肽的神经元受到破坏而导致脑脊液(CSF)降钙素减少有关。更新的诊断标准包括《精神疾病诊断和统计手册》第五版(DSM-5)和《国际睡眠障碍分类》第三版(ICSD-3)。 DSM-5标准要求EDS与以下任何一项相关联:(1)瘫痪; (2)脑脊液降钙素缺乏症; (3)夜间多导睡眠图(PSG)上的REM睡眠潜伏期为15分钟;或(4)多次睡眠潜伏期测试(MSLT)的平均睡眠潜伏期为8分钟,其中有2个睡眠发作的REM睡眠期(SOREMP)。 ICSD-3除了EDS以外,还更多地依赖于客观数据,这使诊断标准更加复杂:1)瘫痪和MSLT / PSG阳性或CSF降钙素缺乏症; (2)与DSM-5相似的MSLT标准,不同之处在于PSG上的SOREMP可算作MSLT所需的SOREMP之一; (3)发作性睡病分为1型和2型,其中1型需要发作性白内障或有记录的脑脊液降钙素缺乏症,而2型是没有发作性白痴,而脑脊液降钙素水平正常或无证。我们讨论了这些标准的局限性,例如在瘫痪的临床表现方面存在差异,特别是在瘫痪可能是模棱两可的情况下,以及在年龄方面;多项和/或侵入性CSF诊断测试要求;并且在某些人群中缺乏规范化的诊断测试数据(例如MSLT)。尽管ICSD-3标准反映了发作性睡病的病理生理学,但DSM-5标准具有更大的临床实用性,这表明将欢迎有效可靠的生物标志物,以帮助进行发作性睡病诊断的标准化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号